Literature DB >> 17153909

Management of difficult germ-cell tumors.

Christie J Moore1, Siamak Daneshmand, G Varuni Kondagunta, Craig R Nichols.   

Abstract

Although testicular cancer is a rare disease accounting for only 1% of all male neoplasms, it represents a paradigm for cancer curability. Overall, more than 95% of patients can expect to be cured of their disease with minimal long-term toxicity. Given these expectations, it is critical that cancer care providers are familiar with the diagnostic and therapeutic challenges encountered in these rare patients. In particular, clinicians managing these patients should be aware of some of the pitfalls encountered when determining relapse. In a series of case presentations, we review the evaluation and management of patients with persistent elevation of serum tumor markers and postchemotherapy residual radiographic abnormalities.

Entities:  

Mesh:

Year:  2006        PMID: 17153909

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  2 in total

1.  Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.

Authors:  Siamak Daneshmand; Hooman Djaladat; Craig Nichols
Journal:  Ther Adv Urol       Date:  2011-08

Review 2.  Management of Residual Mass in Germ Cell Tumors After Chemotherapy.

Authors:  Costantine Albany; Kenneth Kesler; Clint Cary
Journal:  Curr Oncol Rep       Date:  2019-01-21       Impact factor: 5.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.